Principles of adoptive T cell cancer therapy
Top Cited Papers
Open Access
- 1 May 2007
- journal article
- review article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 117 (5) , 1204-1212
- https://doi.org/10.1172/jci31446
Abstract
The transfusion of T cells, also called adoptive T cell therapy, is an effective treatment for viral infections and has induced regression of cancer in early-stage clinical trials. However, recent advances in cellular immunology and tumor biology are guiding new approaches to adoptive T cell therapy. For example, use of engineered T cells is being tested as a strategy to improve the functions of effector and memory T cells, and manipulation of the host to overcome immunotoxic effects in the tumor microenvironment has led to promising results in early-stage clinical trials. Challenges that face the field and must be addressed before adoptive T cell therapy can be translated into routine clinical practice are discussed.Keywords
This publication has 126 references indexed in Scilit:
- Phase I Clinical Trial of Costimulated, IL-4 Polarized Donor CD4+ T Cells as Augmentation of Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2006
- Prolonged exposure of naïve CD8+ T cells to interleukin‐7 or interleukin‐15 stimulates proliferation without differentiation or loss of telomere lengthImmunology, 2006
- Aging of the Immune System: How Much Can the Adaptive Immune System Adapt?Immunity, 2006
- Telomere loss, senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERTBlood, 2005
- Human tumor-specific T lymphocytes: does function matter more than number?Current Opinion in Immunology, 2005
- Mutations inTERT,the Gene for Telomerase Reverse Transcriptase, in Aplastic AnemiaNew England Journal of Medicine, 2005
- Towards patient‐specific tumor antigen selection for vaccinationImmunological Reviews, 2002
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999
- Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative TumorsThe Journal of Experimental Medicine, 1998
- Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow GraftsNew England Journal of Medicine, 1979